Vir Biotechnology VIR
NASDAQ VIR
$11.40 -0.05 (-0.44%)
As of: Sep 4, 2026 · 3:57 PM EDT

Vir Biotechnology (VIR) Notes Payables (2019)

Vir Biotechnology (VIR) posted Notes Payables of $12.4 million for Q4 2019.

Analysis

Vir Biotechnology (VIR) Notes Payables (2019) Analysis & Trends

Vir Biotechnology has reported Notes Payables for 1 years, with the latest figure at $12.4 million in Q4 2019.

  • Quarterly Notes Payables changed N/A year-over-year to $12.4 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $12.4 million (changed N/A YoY) and the FY2019 annual result came in at $12.4 million, changed N/A from the prior year.
  • Notes Payables was little changed at $12.4 million in Q4 2019 per VIR's latest filing.
  • Over five years, Notes Payables peaked at $12.4 million in Q4 2019 and troughed at $12.4 million in Q4 2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Vir Biotechnology 1.92 Bn 1.92 Bn 238.95 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 12.45 Mn